Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 9/20 | 0.48 |
| ▸ | MMP2 | P08253 | 6/20 | 0.48 |
| ▸ | MMP14 | P50281 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1769913 | 0.87 | RAB9A (0.60) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL29878255 | 0.87 | RAB9A (0.60) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4883938 | 0.85 | SRD5A2 (0.43) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL6268309 | 0.82 | GABRA1 (0.35) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL2108919 | 0.80 | KDM4E (0.61) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL9081991 | 0.79 | KDM4E (0.59) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL31370745 | 0.79 | KDM4E (0.74) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4815909 | 0.79 | KDM4E (0.74) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL2107136 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL3955334 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599203-B1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES CONTAINING ACIDIC, MAINLY HETEROCYCLIC GROUPS, CORRESPONDING PRODUCTION METHOD AND USE OF SAID DERIVATIVES AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-8048901-B2 | 5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-8048901-B2 | 5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-8048901-B2 | 5-{3-[3-(5-Methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyloxy]-propyl}-2H-tetrazole; metabolic disorders, insulin resistance, dyslipidemia, Syndrome X | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20080280946-A1 | Azaindole-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
| US-7317027-B2 | 1-substituted 2-carboxamide derivatives of fused ring pyrroles, especially pyrrolo[2,3-b]pyridines and pyrrolo[3,2-b]pyridines, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-08 | — | — | US | disclosed |
| EP-1636226-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101563-A1 | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| US-20040209932-A1 | 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009828-A1 | Azaindole-derivatives as factor Xa inhibitors | F12, F5, F11 | KDM4E 721/4885ALDH1A1 2292/4885HPGD 1537/4885 |
| US-20080249126-A1 | 1,3-SUBSTITUTED CYCLOALKYL DERIVATIVES HAVING ACIDIC, MOSTLY HETEROCYCLIC GROUPS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, FFAR1 | KDM4E 4119/4885ALDH1A1 242/4885HPGD 569/4885 |
| US-20040209932-A1 | 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals | GPR119, PC, CPT1A | KDM4E 4185/4885ALDH1A1 167/4885HPGD 563/4885 |
| US-20080280946-A1 | Azaindole-Derivatives As Factor Xa Inhibitors | F12, F5, F11 | KDM4E 1059/4885ALDH1A1 2202/4885HPGD 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.